Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …

Five-year survival rates for non–small cell lung cancer (NSCLC) range from 14% to 49% for
stage I to stage IIIA disease, and are< 5% for stage IIIB/IV disease. Improvements have been …

Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …

Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC)
is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative …

Purpose To evaluate, in Japan Clinical Oncology Group study 0403, the safety and efficacy
of stereotactic body radiation therapy (SBRT) in patients with T1N0M0 non-small cell lung …

Background Stereotactic ablative radiotherapy (SABR) is increasingly used in the treatment
of medically inoperable early stage non-small-cell lung cancer (NSCLC). Because patterns …

Objectives Long-term survival has been observed in patients with oligometastatic non-small
cell lung cancer (NSCLC) treated with locally ablative therapies to all sites of metastatic …

Importance The incidence of early-stage non–small cell lung cancer (NSCLC) among the
elderly is expected to rise dramatically owing to demographic trends and increased …

Lung cancer is an umbrella term for a subset of heterogeneous diseases that are collectively
responsible for the most cancer-related deaths worldwide. Despite the tremendous progress …

BACKGROUND: Approximately two-thirds of patients with early-stage non-small-cell lung
cancer (NSCLC) in The Netherlands currently undergo surgical resection. As an increasing …